Search the Site

Twitter

test tubes

$CBRX FDA Approval Key to Achieving Sustained Profitability

publication date: Dec 28, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Written by Mike Havrilla-Columbia Labs (NASDAQ:CBRX) is focused on the development of sustained-release products that are based on its bio-adhesive drug delivery technology platform.


Sorry this page is available to subscribers only. 

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:

FREE NEWSLETTER

If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.